Pulmonx raises $3M to create emphysema treatment devices
Pulmonx, a company developing devices to treat emphysema, has raised $3 million in convertible promissory notes, according to VentureWire. The investors in this round are not known.
The Palo Alto, Calif. was founded in 1998, and its technology involves inserting a valve into the lung, shutting off the diseased portion of the lung. It has previously raised $27 million.
Next Story: Xelerated raises $13 million for fast networking chips
Previous Story: Envysion raises $3M to manage video surveillance
About the Author, Anthony Ha
Anthony is VentureBeat's assistant editor, as well as its reporter on enterprise technology, cloud computing, and tech policy. Before joining VentureBeat in 2008, Anthony worked at the Hollister Free Lance, where he won awards from the California Newspaper Publishers Association for breaking news coverage and writing. He attended Stanford University and now lives in San Francisco. Reach him at anthony@venturebeat.com. You can also follow Anthony on Twitter.